Company Overview

Aurora Cannabis Inc. is a Canadian cannabis company headquartered in Edmonton, Alberta, focused on the production, distribution, and commercialization of medical cannabis and consumer cannabis products. The company operates within the global cannabis industry, with activities spanning cultivation, product development, pharmaceutical-style medical cannabis distribution, and consumer packaged cannabis products. Aurora generates revenue primarily through medical cannabis sales, consumer recreational cannabis products in Canada, and international exports to regulated medical markets. Its portfolio includes dried flower, cannabis oils, vapes, edibles, concentrates, and derivative wellness products sold under multiple consumer and medical brands.

Aurora was founded in 2006 and became publicly traded in Canada before expanding aggressively through acquisitions and facility development during the broader cannabis sector expansion following Canadian legalization. The company acquired several cannabis businesses and production assets, including MedReleaf Corp., CanniMed Therapeutics Inc., and Whistler Medical Marijuana Corporation, which significantly expanded its cultivation capacity and international footprint. In recent years, Aurora has shifted toward cost optimization, premium product positioning, and a stronger focus on global medical cannabis markets after industry-wide oversupply and pricing pressures affected profitability across the sector.

Business Operations

Aurora operates through two principal business categories: Global Medical Cannabis and Consumer Cannabis. The medical cannabis business supplies patients and distributors in Canada and international jurisdictions with regulated medical cannabis products, while the consumer segment focuses on the Canadian adult-use recreational market. The company derives revenue through direct patient sales, provincial wholesale distribution agreements, and international exports to pharmacies, medical distributors, and healthcare channels. Aurora has emphasized higher-margin medical cannabis operations as a strategic priority.

The company controls cultivation facilities, genetics programs, manufacturing operations, and distribution infrastructure across Canada and selected international markets. Key operational assets have included facilities such as Aurora Sky, Aurora River, and other indoor cultivation and processing sites designed for pharmaceutical-grade production standards. Aurora also maintains international subsidiaries and partnerships supporting exports into Europe, Australia, and Latin America. Through its medical platform, the company participates in regulated markets where physician oversight and pharmaceutical compliance standards create barriers to entry relative to purely recreational operators.

Strategic Position & Investments

Aurora’s strategy has increasingly centered on disciplined capital allocation, premium cannabis products, and expansion in medically regulated international markets. The company has invested in improving adjusted profitability metrics, reducing operating costs, and streamlining production capacity after earlier expansion phases led to excess infrastructure and impairment charges across the industry. Management has publicly identified international medical cannabis as a long-term growth driver due to higher pricing stability and more structured reimbursement frameworks in several jurisdictions.

Historically, Aurora pursued growth through major acquisitions, including MedReleaf Corp. and CanniMed Therapeutics Inc., which strengthened cultivation expertise, intellectual property, and patient networks. The company has also invested in cannabis genetics, pharmaceutical manufacturing standards, and international distribution capabilities. Aurora maintains exposure to emerging cannabinoid wellness categories and medical research initiatives, although commercial execution in these areas remains dependent on evolving regulatory frameworks. Public filings and company disclosures indicate continued prioritization of international medical markets such as Germany, Australia, and the United Kingdom.

Geographic Footprint

Aurora Cannabis operates primarily from Canada, with its corporate headquarters located in Edmonton, Alberta. The company maintains cultivation, manufacturing, and distribution infrastructure within Canada while supplying both domestic recreational consumers and registered medical cannabis patients. Canadian operations remain central to Aurora’s production base and regulatory licensing framework.

Internationally, Aurora has established a presence across Europe, Australia, and parts of Latin America through export agreements, subsidiaries, and medical cannabis distribution channels. Germany has been identified in company disclosures as one of the most important international medical markets due to the size and maturity of its regulated reimbursement system. Aurora has also participated in markets including Poland, the United Kingdom, and Australia, positioning itself as a global medical cannabis supplier rather than solely a Canadian recreational operator.

Leadership & Governance

Aurora Cannabis is governed by a board of directors and executive leadership team focused on operational efficiency, medical cannabis expansion, and financial discipline. The company’s leadership has emphasized transitioning Aurora from a high-growth acquisition-focused organization into a more sustainable cannabis operator centered on profitability and international medical markets. Public communications and regulatory filings consistently highlight cost control, premiumization, and global medical expansion as strategic priorities.

Key executives include:

• Miguel Martin – Executive Chairman and Chief Executive Officer
• Sanjay Tolia – Chief Financial Officer
• Geoff Hoover – Senior Vice President, Operations
• Andre Jerome – Executive Vice President, Global Business Development
• Kevin Niland – President, Europe

Aurora’s founders included Terry Booth and Steve Dobler, who helped establish the company during the early development of Canada’s legal cannabis industry. Leadership transitions over time reflected broader restructuring efforts across the cannabis sector as companies adapted to changing market conditions, regulatory developments, and investor expectations.